Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Fiche publication
Date publication
mai 2018
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry
Tous les auteurs :
Gilliot S, Sibon I, Mas JL, Moulin T, Béjot Y, Cordonnier C, Giroud M, Odou P, Bordet R, Vivien D, Leys D,
Lien Pubmed
Résumé
Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset. ACE-Is and ARBs have neuroprotective properties in animal models.
Mots clés
Cerebral ischemia, Hemorrhagic transformation, Ischemic stroke, Mechanical thrombectomy, Neuroprotection, Outcome, Thrombolysis
Référence
J Neurol. 2018 May;265(5):1166-1173